Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy
First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer
Submission of MAA in Europe and sBLA in US Anticipated in H2 2023